A Non-Corticosteroid Treatment for Arachnoiditis

By Dr. Forest Tennant

Methylprednisolone and other corticosteroids have been the mainstay of adhesive arachnoiditis (AA) treatment for many years.  AA is a progressive inflammatory spinal disease that causes severe intractable pain, neurologic impairment, and profound functional decline.

Understandably, there has been great resistance by AA patients and physicians to use corticosteroids due to their notorious complications. Corticosteroids are known to cause osteoporosis, hyperglycemia, weight gain, and adrenal suppression. 

Arachnoiditis Hope has been pursuing an alternative treatment for years and we are pleased to report we have discovered one.  Patients and physicians now have a choice. 

The New Alternative

  1. Pregnenolone, 200 mg twice a day

  2. Dehydroepiandrosterone, 200 mg twice a day

  3. Palmitoylethanolamide, 600 to 1200 mg twice a day

Origin of the Treatment

Pregnenolone is a natural hormone made from cholesterol, primarily in the adrenal glands and the brain. Interestingly, pregnenolone was used as the main treatment for rheumatoid arthritis and lupus before corticosteroids were invented.

Pregnenolone and dehydroepiandrosterone (DHEA) are in the same class of natural hormones. They are called “neurosteroids” since they have a similar chemical structure to corticosteroids. However, they do not have the complications of corticosteroids. 

These neurosteroids are naturally produced in the central nervous system (CNS) to suppress inflammation, promote tissue restoration, and relieve pain. 

Palmitoylethanolamide (PEA) is another natural biochemical produced by the body to control inflammation, restore tissue, and provide pain relief. 

This new AA treatment can be initiated at any time. When taken together, these 3 medicinals have a potent anti-inflammatory, healing, and pain relieving effect. They can be used separately, but the three together are much more effective.

DHEA may cause hair loss or bleeding irregularities in pre-menopausal women. Reduce the dosage in these cases. Overall, there are far fewer side effects than corticosteroids.

New Handbook

To learn more about neurosteroids, please see my new handbook, “Primer on Neurosteroids and Chronic Pain Care.”

Neurosteroids are beneficial not just for AA patients, but for anyone with chronic pain, as they help heal damaged tissues, protect and regenerate nerves, and provide pain relief. 

There is a plethora of laboratory and human studies that pave the way to use neurosteroids in chronic pain care.

Their use in pain care improves pain control and lessens the need for opioids. 

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its bulletins here. 

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section.    

First Successful Treatment of Arachnoditis Published  

By Dr. Forest Tennant

For the first time since arachnoiditis was identified and defined in medical dictionaries in 1873, patients and physicians now have a successful peer-reviewed treatment for chronic adhesive arachnoiditis (AA). 

I and my associates, Dr. Martin J. Porcelli, and Jennifer Sands, RN, have just published the results of a small study, “Low Dose Methylprednisolone and Ketorolac Treatment for Adhesive Arachnoiditis” in the International Journal of Emergency Medicine & Pain Management.

AA is a progressive inflammatory spinal disease in which cauda equina nerve roots become bound by adhesions to the arachnoid membrane, often resulting in severe intractable pain, neurologic impairment, loss of mobility, bowel and bladder dysfunction, and profound functional decline.

In our study, 20 patients with AA achieved symptomatic pain relief with low, intermittent dosages of the corticosteroid methylpredisolone and ketorolac, a non-steroidal anti-inflammatory drug (NSAID). The key goal in using these two drugs is to suppress inflammation. 

Low doses of methylpredisolone 4mg and oral ketorolac 10mg (or injectable ketorolac 15-30mg) were given to patients 1 to 3 days a week. Participants took the combination for 30 to 180 days.  

Seventeen of the 20 patients reported improved pain control, 13 reported improved physical activity, and 9 reported fewer bedbound days. Most patients also reported fewer pain flares and a decreased intensity of their flares. 

It is fitting that the first published treatment for AA is ketorolac and methylprednisolone. These two drugs have been the most reliable and consistent medicinals for AA. 

The absence of a published treatment for AA for 153 years has left patients in a dangerous vacuum. Into that vacuum came dismissal, therapeutic nihilism, medical abandonment, and the repeated phrase so many patients have heard: "There is nothing that can be done." This publication changes that conversation.

This does not mean the search for AA treatment is complete. It means the era of saying that nothing has ever been published must end, and a new treatment-development era has begun.   

Going forward, we believe the new treatment can be combined with neurosteroids, biologic pain relievers, neurohormones, and peptides for even better results. Let’s hope that this first study is just the beginning.

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its bulletins here.

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section.   

Doctor, the Patient Will See You Now

By Julie Titone

Have you ever gone to an appointment with a new doctor, hoping to meet Patch Adams, the true story of a compassionate and funny doctor played by the late Robin Williams in a 1998 movie?

Instead of Dr. Adams, you find Dr. Doom waiting in the exam room. 

My experience hasn’t been that extreme, but there are certainly physicians I wouldn’t recommend. Or revisit.

I say this in the wake of my annual checkup with a primary care doc who cheerfully answered my inevitable list of questions. She remembered that my mom is 102, and suggested I may have another 30 years ahead (oy). 

After four years, she knows me. When I asked if she would continue being my doctor as I age, she said, “I’m not going anywhere.” 

Good to know! Because finding and adjusting to a new healthcare provider can be fraught.

In fact, among those of us with adhesive arachnoiditis, there are few hotter topics than where to find someone willing to treat our chronic, uncommon and often debilitating form of spinal nerve damage. One man told me that a new doctor literally backed out of the exam room upon seeing the arachnoiditis diagnosis on his chart.

I’ve come to think of office visits as stage plays. The opening act —  that first appointment – features two characters who are wary of each other. 

Let’s say the patient has been disappointed by previous doctors and is worried about the cost of treatment. Her emotions are rubbed raw by unrelieved pain. On top of all that, she has little trust in what my pain specialist calls, with an ironic eye roll, “our health care system.” (One study determined that, from 2020 to 2024, public trust in doctors and hospitals plummeted from 71 to 40 percent.)

The doctor, meanwhile, has dealt with all manner of personalities and diagnoses that day, and has no idea what awaits behind the exam room door. He hasn’t had sufficient time to even read the patient’s lengthy chart because he was busy dealing with insurance companies, on top of a packed schedule.

There may be too much ego or too few communication skills present in an exam room. A doctor’s deep experience – in general, a good thing – can get in the way of seeing a patient as an individual who might differ significantly from previous patients with similar symptoms. 

I once saw a doctor who clearly was brilliant. She bombarded me with questions, but then didn’t give me time to properly answer them.

I do see improvement in doctors’ acceptance of patients who have done their own health research. We’ve come a long way since about 20 years ago, when I asked an informed question of a doctor who responded, “Oh, you’re one of those internet people.” 

In the case of rare diseases, patients are quite likely to know more about their condition than the physician does. That should be a chance for mutual problem solving, not wisecracks about Dr. Google.

Sure, there are genuine cases of “cyberchondria.” Some people are bound to misdiagnose themselves and catastrophize. But that seems like a lesser problem than having people show up at clinics totally uneducated on matters of health.

If I were a physician, I might relish the challenging cases. But I’m not sure I would have the emotional stamina that the job requires, especially if it involved seeing people in pain, day in and day out. Simply dealing with an endless parade of suffering humans could be taxing.

Let’s hope there are always doctors who get enough satisfaction out of helping people, so that they’re willing to put up with the downsides and stick with the profession. We need them.

Julie Titone is a journalist who frequently writes about health issues. Find her work at julietitone.substack.com/. 

Methylene Blue: A New Pain Relief Option

By Dr. Forest Tennant

Over the past 1-2 years, the fatty acid palmitoylethanolamide (PEA) was found to reduce pain and inflammation. PEA occurs naturally in our bodies and in some foods, and is sold in over-the-counter supplements.  

PEA has been urgently needed because of the poor accessibility of opioid pain medication. The menu of non-opioid pain relievers is small: ketamine, oxytocin, CBD, marijuana, and kratom.  

I am pleased to add methylene blue (MB) to the list. Every adhesive arachnoiditis (AA) patient needs to try PEA and MB. One can no longer be confident that their doctors and insurance plans will cover opioids. 

Methylene blue is a salt first used in the 1870’s as a textile dye. It was then used medically as an anti-malaria drug and to treat a rare blood disorder called methemoglobinemia. 

MB has also been used off-label for a variety of medical conditions. Its best-known value has been for the treatment of severe pain associated with head and neck cancer.

About a year ago, Arachnoiditis Hope began receiving reports that MB was being used by persons with AA. Some had stopped taking opioids or were no longer able to obtain them.

There are multiple ways to purchase MB online as a supplement. MB is typically sold as a liquid taken orally, or in capsules and gummies. It is inexpensive and the recommended dosage is on the label. 

AA patients can take MB to boost the effect of opioids or PEA. It is important to note that MB is a monoamine oxidase inhibitor, so patients who are taking an anti-depressant should not take it.

The medical world is well aware of the CDC opioid guidelines and the prosecution of physicians who prescribed high dose opioids. For the most part, there was not a governmental assault on the use of short-acting low potency opioids, such as tramadol and codeine. 

I cannot identify a single case in which a physician was disciplined for prescribing a short-acting, low potency opioid to an MRI-documented case of AA.

The movement to force all patients to stop taking potent long-acting opioids doesn’t seem to be calming down. Their goal is to stop patients from taking high dose opioids and to use electric stimulators, intrathecal pumps, or buprenorphine/methadone. 

Every AA patient needs to be aware of PEA and MB as alternatives. 

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its research bulletins here.   

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section. 

PEA: A Supplement That Helps Reduce Pain and Inflammation

By Julie Titone

It is a question I’ve long had but never bothered to look up: How do drugs get their names? Then I heard about palmitoylethanolamide and, given it has the longest name of anything I ever considered consuming, I had a solid reason to pursue the question.

PEA, as the tongue-twister is unsurprisingly known, isn’t a prescription drug. It’s a fatty acid found naturally in our bodies and in some foods. PEA can also be manufactured and is sold in over-the-counter supplements. It binds to cells in the body and reduces inflammation and pain.

When a fellow arachnoiditis sufferer called it to my attention, I read up on it.

PEA was first identified in the 1950s, after doctors observed that children who ate eggs were less likely to get rheumatic fever. Early studies found PEA not only in the fatty solids of egg yolks, but also in components of peanuts and soybean lecithin.

Researchers found that the compound had anti-inflammatory effects in animal models, and noticed it could also reduce allergic reactions. That lead to early clinical trials for conditions like influenza and the common cold.

Interest in PEA then dropped off for two decades. It was revived again thanks in large part to Nobel Prize-winning neurobiologist Rita Levi-Montalcini. Her work in the 1990s and 2000s helped establish PEA's role in modulating mast cells, which are key players in inflammation and allergic responses. She was a huge fan of PEA, reportedly taking it herself. She lived to be 103.

Interest in PEA is strong and getting stronger. For two recent reports, researchers analyzed scores of studies, tabulated the results of the rigorous ones, and reached upbeat conclusions.

The 2023 meta-analysis in the Swiss journal Nutrients looked at PEA’s effect on chronic pain, and found “PEA was associated with improved functional status and quality of life in many studies, while reported side effects were essentially negligible.”

A 2025 meta-analysis published by the journal Nutrition Reviews confirmed that “PEA effectively reduces pain and enhances quality of life, with significant benefits observed within 4-6 weeks of treatment. Palmitoylethanolamide is a promising alternative to chronic opioid analgesics, potentially reducing the risk of opioid abuse and dependency.”

That last point — that PEA could provide a safe alternative to opioids — is a big driver of interest in the nine-syllable compound. Researchers are also looking at its promise in treating long Covid, glaucoma, Alzheimer’s, Parkinson’s, ALS and more. So far, it’s shown to be most effective in the treatment of neuropathic pain.

To make PEA more effective, researchers have figured out how to make it more available in the body. Thus “micronized,” PEA is now available in some countries as a prescription drug. Why didn’t that happen earlier? For one thing, drug manufacturers apparently didn’t see great promise or profit in it.

Chemists also discovered PEA before the United States and WHO came up with national and international naming councils, which give drugs generic names such as ibuprofen.

Manufacturing marketing teams are the ones who come up with brand names. Though I find it hard to picture a room full of those folks looking at PowerPoint slides, rubbing their chins thoughtfully until someone exclaims “Yes! Let’s call it Advil! That certainly says ‘Be gone, demon headache’ to me!”

Am I taking PEA? Yes, dear reader, I am. For the past three weeks. Because the research says it takes four to six weeks to see results, I have nothing to report. Perhaps PEA won’t show definitive improvement, but works in the background to keep my inflammatory spinal disease from getting worse.

I would certainly take that outcome from a supplement that is readily available, doesn’t break the bank, and has no side effects.

Following a career in journalism and academic communications, Julie Titone writes about health, environment and other issues at julietitone.substack.com.

The Basic Protocol for Treating Adhesive Arachnoiditis 

By Dr. Forest Tennant

When Arachnoiditis Hope was formed eight years ago, we had enough experience under our belt to know that treatment of adhesive arachnoiditis (AA) required 3 medical components: 

  1. Suppression of inflammation

  2. Regeneration of the cauda equina and arachnoid membrane

  3. Relief of pain 

Our recommended basic protocol has evolved over the past eight years, based on our review of about 2,000 AA cases. This treatment protocol has been consistently successful in treating most AA cases.  

The basic protocol represents our best approach to stop deterioration. Once established, we recommend additional measures in an attempt to permanently reduce pain and neurologic impairments.

The starting treatment protocol:   

Relief of Pain

Choose a short-acting opioid for pain flares and exacerbations.

Options include less potent opioids, such as tramadol, codeine, buprenorphine, and hydrocodone or oxycodone with acetaminophen 

More potent opioids include oxycodone (plain), morphine, fentanyl and hydromorphone

Suppression of Inflammation and Autoimmunity

  • Methylprednisolone 4 mg or dexamethasone 0.5 or 0.75 mg two or three days a week

  • Ketorolac 10 mg with meals 2 days a week or a 15 to 60 mg injection one day a week

There are alternatives to corticosteroids and ketorolac, but they do not appear as consistent or effective.

Regeneration of Cauda Equina and Arachnoid Membrane

Dehydroepiandrosterone (DHEA) 200 mg in AM and PM

Additional Measures

Supportive Diet, Vitamins and Minerals: The basic protocol is supported by a daily protein, low carbohydrate, sugar-restrictive, anti-inflammatory diet (daily fruits and vegetables), plus vitamins C, B-12, D and the minerals, magnesium and selenium.

Spinal Fluid Flow Exercises: Rocking in a chair or gentle bouncing on an indoor trampoline are recommended.

Advanced Treatment: After a person is stabilized on the basic protocol, some additional measures that are designed to permanently reduce pain and symptoms can be added. These include peptide/hormone administration, Epstein-Barr virus eradication, adhesion dissolution, electromagnetic therapy, and central pain therapy.

As we approach the end of 2025 we hope you have received some benefit from our efforts to help those suffering with adhesive arachnoiditis and related conditions.  We will likely start a new bulletin series in 2026.  You may wish to print or download and save some of our bulletins from 2025.

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its research bulletins here.   

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section. 

On a Scale of 1 to 10…

By Julie Titone

Pain is the most common reason that people see a primary care doctor. If you have chronic pain – the kind that’s stuck around for three months or more – chances are you’ve seen lots of specialists, too. 

You may dread their standard question as much as I do: “On a scale of 1 to 10, how much pain do you feel, with 10 being the worst pain possible?”

I hesitate to answer. If I say 6, will I feel like a whiner? If I say 5, will my pain be taken seriously? 

How would I know if I felt the worst possible pain? 

Are you asking me how much it hurts when I stand or when I sit?

There is value in trying to quantify pain, and many have tried to improve upon the 10-point scale. But pain can never be captured by numeric language or, for that matter, by the English language. Good doctors are less interested in numbers than in how the pain is affecting someone’s life.

This subject is on my mind because of the responses to my column, “Arachnoiditis: My Not-So-Rare Disease.” 

Readers who share my diagnosis of adhesive arachnoiditis told me they appreciated my effort to spread the word about this chronic inflammatory disease. But a few chided me for downplaying how painful arachnoiditis can become. 

Here is what I wrote: “Patients experience lower body numbness and stinging pain that, at its worst, is likened to hot water dripping down the legs. The disease can lead to paralysis and bladder dysfunction.”

I debated which words to use in that paragraph. A litany of misery might cause folks to stop reading, so I kept the descriptive list short. 

Now, in recognition of those who suffer, I will expand upon the kinds of pain reported by arachnoiditis patients:

  • Burning, stabbing, shocking, zapping

  • Buzzing, icy hot, insects crawling under the skin. 

  • Deep aching/boring in the spine. 

  • Pain radiating down the back of the legs. 

  • Vice-like pressure. Cramping. 

  • Pain that increases upon standing or sitting. 

  • Sudden flares triggered by movement. 

  • Widespread burning in the lower body. 

  • Pelvic, abdominal and bladder-related pain. 

  • Unrelenting, throbbing, exhausting pain.

As one woman wrote in an online discussion: “How much can a body take?” 

Some patients would answer that question with suicide.

What makes this all doubly sad is that arachnoiditis often begins when people seek relief, via injections or surgery, from another source of pain.

So far, my own arachnoiditis is not debilitating. I get modest relief from medicines, movement and massage. Distraction helps. If you need advice on the best ice packs and seat cushions, I’m your gal.

Chronic pain plagues an estimated 20 to 30 percent of people in the world at any given time. The cliché goes that misery loves company. I don’t love it, but that massive company could work in my favor someday.

Researchers have 2 billion reasons to investigate pain treatment and prevention. As the secrets of neural pathways are unlocked, the knowledge is bound to benefit those of us with arachnoiditis.

Julie Titone is a former newspaper journalist who also worked in academic and library communications. She is retired and lives in Everett, Washington. Julie’s website is julietitone.weebly.com.

This column first appeared in Julie’s Substack blog and is republished with permission. 

Arachnoiditis: My Not-So-Rare Disease

By Julie Titone

I first heard the word “arachnoiditis” from the spine surgeon who performed my lumbar fusion. This was a virtual office visit. I leaned into my laptop screen to say: “That sounds like a spider.”

“Yes,” he replied.

He had identified the source of my unexpected post-op pain: arachnoiditis, a chronic inflammatory disease that’s even creepier than it sounds. Its symptoms usually arise after spinal trauma due to surgery, injury or commonly prescribed injections. 

More doctors and patients should know about this small chance of a very big problem.

Arachnoiditis is so far incurable, difficult to treat, and can get worse over time. Patients experience lower body numbness and stinging pain that, at its worst, is likened to hot water dripping down the legs. The disease can lead to paralysis and bladder dysfunction. While arachnoiditis is said to be rare, it could simply be under-diagnosed.

The arachnoid is a membrane with a webbed appearance, hence its spidery name. It is part of the sheath that encloses the spinal fluid. Arachnoiditis is the inflammation of that easily annoyed membrane. 

Sometimes it causes free-floating spinal nerves to stick together and become locked down by scar tissue. This is known as adhesive arachnoiditis, the kind I’m describing here.

No one knows how many spinal surgeries result in arachnoiditis, but a common estimate is 3 to 6 percent. Propelled in part by the deteriorating backs of boomers like me, there were more than 340,000 such surgeries in 2023 in the United States. 

Just 4% of that adds up to 13,600 people suffering from arachnoiditis in a single year in a single country. The number doesn’t include cases that emerge after spinal injections of anesthesia or steroids, or after accidents that damage the spine.

‘They Stuck Me Eight Times’

Sara Lewis was a young Florida nurse when, on New Year’s Eve in 2008, she required an emergency Caesarean section. Attempts to give her anesthesia before the surgery did not go well.

“They stuck me eight times to get the spinal block in,” she recalled. 

Lewis left the hospital with a baby boy and excruciating pain. She went back to work, eventually switching to a less-demanding job. By 2014, she couldn’t work at all and didn’t yet have a proper diagnosis. By 2017, she had qualified for disability benefits. Lewis is only 44.

Many women choose epidurals to ease pain during normal vaginal deliveries. Unlike a spinal block, an epidural delivers anesthesia in a space outside the spinal fluid sac. Even that approach poses risk when done poorly.

Arachnoiditis sufferer Steve Lovelace would like women to consider that pain relief during childbirth might not be worth risking a lifetime of suffering. “I know so many women who have children and are in so much pain during what should be the most joyful part of their life,” he said.

Lovelace’s agony started with a freak tree-cutting accident in 1982 on an Oklahoma family farm. His 20-year-old torso was crushed, causing debilitating injuries that required multiple surgeries. 

Now 63 and medically retired from a radiology career, the pioneering para-triathlete has teamed up with Lewis to create the YouTube podcast Arachnoiditis Unfiltered. Given what they endure, they are remarkably chipper co-hosts. Their goals: awareness, prevention and a cure.

Lori Verton aims for those goals, too. Verton lives near Ontario, Canada. In 1999, she was driving out into the dark on a mission to buy milk for her kids. She was injured when her car hit a deer. When her whiplash symptoms didn’t improve, her doctor ordered a spinal tap.

“While I was on the table, I felt my left thigh go numb, my left foot drop, I was incontinent. I knew immediately something was wrong,” she recalled. “They said, ‘We’ve bruised some nerves, it will heal.’”

Heal it did not. She was increasingly disabled by pain and estimates it took five years and a dozen doctors to diagnose arachnoiditis. Largely bedridden at age 42, she went on disability. Having worked as a physiologist and medical researcher, Verton pondered how to put her skills to use. That led to the creation of the Arachnoiditis and Chronic Meningitis Collaborative Research Network.

‘No One Knew Anything About It’

Forrest Tennant, a retired physician, is widely associated with arachnoiditis. The disease is the focus of his small foundation and Arachnoiditis Hope website. 

I watched a video in which Dr. Tennant said one hallmark of arachnoiditis patients is they are always moving. I thought: Ah, he knows us. With pain focused on lower backs, buttocks and legs, many arachnoiditis patients can’t sit comfortably. Nor, if they can stand, can they stay in one spot for long. Some can barely sleep.

I asked Dr. Tennant what spurred his interest in the disease. He said it was the number of people with the same symptoms who were coming into his pain clinic, and the high suicide rate among them. 

“I found out no one was interested in the disease, no one knew anything about it. Patients were so grateful for any help they could get,” he told me.

Dr. Tennant said doctors from around the world contact him, seeking treatment advice. I don’t doubt it. I’ve read journal articles written by doctors from Poland, Brazil and China, scouring the medical literature for anything they can find on the subject. The authors of a recent case study described the literature on the disease as “vague and outdated.”

Dr. Tennant doesn’t dispute the value of injections for spinal pain, but said they can set people up for trouble, especially if they are repeated. He’s seen patients who had as many as 20 epidurals. 

When we talked, I added up my own spinal intrusions. The first was a Caesarean. My preemie baby was arriving upside down and backward, so there seemed no alternative to spinal anesthesia there. 

The second instance was a steroid injection aimed at reducing chronic pain that arose after hip replacement. It was a Hail Mary treatment that didn’t help. 

Finally, in 2024, I had that single-level lumbar fusion. Four doctors had predicted dire health consequences if I didn’t get my spine reinforced. One physician confirmed my arachnoiditis diagnosis. As that surgeon was leaving the exam room he turned and said, “What would bother me is not knowing.” 

In other words, not knowing why I developed arachnoiditis after my back surgery. Most patients don’t.

More Can Be Done

There’s a crying need for research into the causes of arachnoiditis. I find it hard to muster hope for significant advancement in the U.S., where federal health budgets have been slashed. 

Still, there’s much that could be done to prevent and identify the disease. Medical schools could call attention to arachnoiditis as a possible cause of pain. Patients could be asked routinely about their history of spinal injections and counseled on the risks of doing more. All radiologists could be trained to spot arachnoiditis. 

There could be a diagnostic code specific to the disease, making it easier to document and study. Spine surgeons, who know that arachnoiditis is consigning some patients to a lifetime of pain, could lead the charge to determine its cause.

Meanwhile, I’m depleted by stories like Matt’s. The 38-year-old Michigan man asked me not to share his last name, afraid that his disability could lead to job discrimination. 

On July 18, 2023 – he’ll never forget the date – Matt was given steroid injections on both sides of a bulging disk. His back pain immediately increased. Then it spread. Now, he said, “I pretty much avoid doing everything else I used to do in my life, because it hurts.”

As I cope with arachnoiditis, I ponder how to spread the word about it. Maybe this disease needs a simpler name. It definitely could use a champion – so far, no celebrity has joined forces with arachnoiditis patients. If only Spiderman would come to our rescue.

Julie Titone is a former newspaper journalist who also worked in academic and library communications. She is retired and lives in Everett, Washington. Julie’s website is julietitone.weebly.com.

This column first appeared in her Substack blog and is republished with permission. 

The Underlying Causes of Chronic Pain Need Treatment, Not Just Symptoms

By Dr. Forest Tennant

In today’s healthcare system, a single disease or condition is usually given to a person as the cause of their severe chronic or intractable pain. These common labels include Complex Regional Pain Syndrome (CRPS), adhesive arachnoiditis, pudendal neuropathy, traumatic brain injury, small fiber neuropathy, and osteoarthritis.

The singular diagnosis is usually the more prominent cause of pain – and is often required for record keeping, insurance coverage, justification for medicinals, and for diagnostic testing.

An emerging fact, however, is that the person who has severe chronic pain and requires daily symptomatic relief almost always has pain in more than one body system or anatomic site. For example, in a recent study we found that persons with adhesive arachnoiditis have an average of three to four other painful conditions. This reality is best called by an older medical term: “multi-system disease.”

A multi-system disease is one that has a single cause that affects multiple body systems. Historically, an infectious bacteria or virus has been the cause of multi-system disease. The best known are syphilis and tuberculosis. The former originates in sex organs and the latter in the lung, but both infections can travel through the blood, infecting and forming disease in multiple body systems, such as the brain, spinal cord, and adrenal gland.

In the late 20th century, diabetes and autoimmune diseases such as systemic lupus became known as causes that may affect multiple body systems. In this century, it has been discovered that genetic connective tissue diseases such as Ehlers-Danlos syndrome, Lyme disease, and the Epstein-Barr virus may affect multiple body systems and produce chronic pain.

Some patients develop severe chronic pain as a result of trauma or injury to a single body system, such as the brain, spine, joints and nerves. The pain may initially remain localized to that one body system. The majority of persons in pain treatment, however, subsequently develop pain in other anatomic locations or body systems.

The genetic, infectious, and autoimmune causes of multi-system disease appear to all be progressive, with a proclivity to affect, over time, additional tissues and systems. Our view is that the progressive nature of multi-system disease may not just cause intractable and disabling pain, but may also lead to the impairment of physical and mental functions that severely incapacitate an individual. Suicide or a shortened lifespan may be involved in severe cases.

Modern day pain treatment is fundamentally about symptomatic relief.  This includes opioids, neuropathic agents, anti-inflammatory drugs, and electromedical measures. It’s time that we recognize that the underlying causes of chronic pain should also be treated, and not just the symptoms. This is a clarion call to recognize multi-system diseases, determine their underlying cause, and simultaneously treat them and the pain that they cause.

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its research bulletins here.  

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section.    

On August 16, Dr. Tennant is hosting a free seminar in Westminster, Colorado on the latest research and treatments for adhesive arachnoiditis. Visit the conference website or click on the banner below for more information. All attendees are encouraged to register by August 1.

Learn the Latest Advances in Adhesive Arachnoiditis at a Free Seminar

By Pat Anson

If you suffer from adhesive arachnoiditis (AA) or would like to learn more about it, there’s a unique opportunity next month to learn about the latest research and treatments for AA, and to connect with other patients, advocates and physicians.

The Tennant Foundation and the Arachnoiditis & Chronic Meningitis Collaborative Research Network (ACMCRN) are hosting a one-day seminar on Saturday, August 16 in Westminster, Colorado outside Denver. Lodging, meals and transportation are not provided, but the conference itself is free of charge.

AA is a spinal disease that causes chronic inflammation in the arachnoid membrane that covers the spinal canal. When nerves in the spine also become inflamed, they can adhere or stick together, causing severe pain and a wide variety of other symptoms.  

AA can develop after surgery or trauma that damages the spine. It may also be triggered by an inflammatory autoimmune disease that originates outside the spine that spreads into spinal tissue.

There is no cure for AA, but advances are being made in its treatment. The problem is that few practitioners know how recognize the early symptoms of AA, much less how to diagnose and treat it. That’s why conference organizers hope physicians will attend, along with patients, caregivers and family members.   

“We'll take whoever is interested,” says Dr. Forest Tennant, who is recognized as the world’s leading expert in AA. “We'd like to have many nurse practitioners or physicians who really want to know the disease. We're going to cover it backwards and forwards. We hope to make them educators and advocates for the disease.”  

Tennant has developed a unique protocol to treat AA not only with pharmaceuticals, but with hormones, vitamins and supplements that can help ease the symptoms and slow or prevent the disease from spreading.

“I want to get across the point that treating arachnoiditis is no more difficult than treating emphysema or rheumatoid arthritis or high blood pressure. It can be done in a primary care setting quite easily. It is not something that has to be done at the Mayo Clinic or in a sophisticated medical setting. It can be done in any office,” says Tennant.

Also speaking at the conference is Eve Blackburn, VP of Patient Engagement for ACMCRN, who will talk about the resources her organization has for patients, including a list of physicians that treat AA.  

“I’ll be sharing an update on the relaunch of the International Arachnoiditis Patient Registry, which is currently undergoing final steps in the ethics review process. We anticipate reopening within the next two months through our new secure platform, Digital Cabinet. I’ll also highlight our growing peer support programs, our referral list of Arachnoiditis-aware physicians, and the wide range of educational resources available at acmcrn.org,” said Blackburn.

The conference is not just for people diagnosed with AA. Since the disease is often associated with autoimmune disease or other types of spinal problems, patients suffering from those conditions could also learn important lessons at the seminar.  

“I call them associated diseases. Ehlers-Danlos syndrome, Tarlov cyst, and the Epstein Barr virus, those three in particular, as well as other spinal conditions. You can't talk about arachnoiditis unless you're also talking about autoimmunity and these other conditions that are high risk factors for developing the disease,” says Tennant.

The August 16 seminar is being held at the Marriott Hotel in Westminster, Colorado — which a special rate for conference attendees. Click here for more details.

You can also visit the conference website for hotel information and list of phone numbers to call if you have any questions. All attendees are encouraged to register by August 1.

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its research bulletins here.

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section.   

Descending Pain: A New Way to Control Severe Chronic Pain

By Dr. Forest Tennant and Ingrid Hollis

The control of severe chronic pain in medical practice today is almost exclusively based on “ascending” or “neuropathic” pain:

Ascending pain occurs when a pain signal is transmitted from the site of injury or disease up the spinal cord to the brain. Neuropathic pain is the pain that results when there is damage or dysfunction of nerve tissue in the brain, spinal cord or peripheral nerves. 

In recent years, researchers discovered that when chronic pain centralizes, it creates a third type of pain called “descending” pain. This is a critical issue for persons with adhesive arachnoiditis and other diseases that cause severe chronic pain, because descending pain requires different medications than those used for ascending and neuropathic pain.

A person with constant pain will produce excess bioelectricity (central sensitization or centralized pain) in the glial cell matrix of the brain. This bioelectricity “descends” or travels down the spinal cord and vagus nerve. It not only produces pain, but over-stimulates the cardiovascular system. 

Descending pain is controlled by the noradrenergic receptor.  The neurotransmitter to this receptor is called noradrenalin or norepinephrine. 

Symptoms of Descending Pain

Descending pain will be present in persons who have constant, unremitting pain. Here are the symptoms:

  • Pulse rate elevates

  • Periodic hot flashes

  • Cold hands/feet

  • Excess sweating

  • Allodynia (pain upon light touch) 

Over-Reliance on Opioids and Neuropathic Agents

The lack of awareness about descending pain is one reason why high doses of opioids and neuropathic agents (i.e., gabapentin, diazepam) may be over-prescribed. Physicians may simply raise the opioid or gabapentin dosage if they are not aware that the cause is descending pain.  What’s more, the increase in dosage may be ineffective or even harmful.

This also applies to opioids in implanted pumps.  Countless persons have been treated with an implanted device or “pain pump” with the erroneous belief that no medication, except intrathecal opioids, are needed.  Patients with these devices soon learn that their pain is poorly controlled by opioids alone. 

Opioids and neuropathic agents have little effect on descending pain.  It must be treated separately.

Pain treatment and relief are based on a medicinal that activates or stimulates a specific receptor (think “action point”) that is present in nerve cells in the brain, spinal cord or peripheral nervous system. Here is how the three types of pain and their receptors can be treated:

  1. Ascending pain needs to be treated with medications that activate the endorphin or opioid receptor. 

  2. Neuropathic pain control depends on activation of a receptor called gamma amino butyric acid (GABA). 

  3. Descending pain control must activate the norepinephrine (noradrenalin) receptor.

To achieve good control of severe, chronic or intractable pain, all three of these receptors must be simultaneously activated.  Severe chronic pain is commonly undertreated, because all three receptors are not simultaneously activated.

Medication Classes for Descending Pain

Three medication classes are used to treat descending pain.  Medical practitioners and patients have choices, and can experiment to help decide which medications and supplements bring the most comfort.

  1. Bioelectric Blockers: Tizanidine, propanolol, clonidine, tapentadol (Nucynta).

  2. Receptor Activators: Modafanil (Provigil), methylphenidate (Ritalin), dextroamphetamine, amphetamine salts (Adderall), phentermine, lisdexamfetamine (Vynanse). Non-prescription activators: lion’s mane, mushroom extract, St. John’s wort, rhodiola, mucuna, whole adrenal gland.

  3. Precursor (Amino Acids) of Noradrenaline: Phenylalanine at 1,000 to 2,000mg a day. Tyrosine at 1,000 to 2,000mg a day.

When not controlled, chronic pain, inflammation and autoimmunity will deplete a number of neurotransmitters and hormones.  When that happens, noradenaline (norepinephrine) will often be depleted. 

Supplements of either amino acids (phenylalanine or tyrosine) and daily protein intake may help reduce both background and flare pains. Phenylalanine and/or tyrosine need not be taken every day, but they are highly recommended at least two days a week. They can and should be taken with a bioelectric blocker or receptor activator.

Noradrenergic receptor activators do not raise pulse rate or blood pressure in a constant pain patient like they do in a normal person.  They may actually lower blood pressure and pulse rate.  That’s because chronic pain, inflammation and autoimmunity deplete noradrenalin.

One medication, tapentadol (Nucynta), is both an opioid and norandrenergic blocker. It is highly recommended.

Descending pain is a new discovery that must be recognized and controlled to achieve relief from severe chronic pain.  A sole reliance on opioid and neuropathic agents may often provide inadequate pain relief.

To learn more about descending, ascending and neuropathic pain, you can watch a recent episode of DocToks with Dr. Forest Tennant and Friends.

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its bulletins here.

Ingrid Hollis is a person in pain, patient advocate, and advisor to the Tennant Foundation.

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section.   

Care and Control of Adhesive Arachnoiditis Depends on Water

By Dr. Forest Tennant

Chronic illness tends to decrease one’s desire to drink fluids. If you have Adhesive Arachnoiditis (AA), however, you must drink some fluids about every 2 hours while awake. Why?

AA is an inflammatory disease of the spinal canal in which cauda equina nerve roots become attached by adhesions to the arachnoid-dural membranes covering the spinal canal. 

The arachnoid membrane is unique among tissues in the body as it doesn’t have its own blood supply. No arteries feed into it. Consequently, it depends on a “full tank” of spinal fluid that comes from the fluids you drink. Spinal fluid brings nutrients and medication to the arachnoid. It also bathes the inflamed area and washes away inflammatory waste and toxins.

Spinal fluid must be constantly kept at a high level. The body makes about 500 milliliters (17 ounces) of spinal fluid a day. If you are dehydrated due to lack of regular fluid intake, you may not make enough spinal fluid to control AA, including its pain.

Water Soak Every Day

Soaking in water daily is also important to control pain and inflammation from AA.

Water soaking is an age-old remedy for pain that is still worthwhile. It is believed to relieve pain by relaxing muscles and increasing blood flow to damaged areas of the body.  

Water soaking also extracts excess bioelectricity and inflammatory toxins that have accumulated due to inflammation and damage to the neurologic circuitry in the body. 

Here is a list of water soaking measures that are applicable to a person with AA: 

  1. Stand in the shower and let water flow off your back, neck and legs.

  2. Immerse your body up to your neck in a bathtub, hot tub, jacuzzi or pool.

  3. Drape a warm, water-soaked towel over your back.

  4. Soak your feet and ankles in warm water.

The soaks should be done for 5 to 15 minutes. Minerals or herbs can be put in foot baths. The most popular mineral preparation is Epsom Salts.

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its research bulletins here.

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section.   

The Two Most Common Causes of Adhesive Arachnoiditis

By Dr. Forest Tennant

Adhesive arachnoiditis (AA) doesn’t just happen out-of-the-blue or overnight. It is the tragic end result of sequential pathologic damage, over time, to multiple spinal tissues.

AA may develop from a direct spinal injury or from an inflammatory, autoimmune disease that originates outside the spine.  The discovery that inflammatory-autoimmune diseases can originate outside the spine and spread into spinal tissue is a new medical concept.

Here are the two common pathologies that can cause AA, and the early symptoms that precede AA itself:

Pathology #1: Spinal Trauma

The first pathologic journey is accidental spine trauma or a medical procedure such as an epidural injection that damages the spinal canal cover, which consists of an outer layer (dura) and an inner layer (arachnoid).

Direct spinal injuries may occur to persons in good health.  Examples are auto accidents or electrocution in an industrial accident. The arachnoid layer becomes inflamed after trauma, just like a finger that has been hit with a hammer. The inflammation may progress and then spread.

Eventually, the inflammation will contact cauda equina nerve roots and spread into them. After a time ranging from weeks to months, the inflammatory adhesions “glue” cauda equina nerve roots to the arachnoid, forming the disease called adhesive arachnoiditis.

Pathology #2: Degenerative Discs

Spinal discs degenerate when they become inflamed, due to a pathologic generator such as an infection, autoimmunity or trauma.

Persons who have a genetic connective tissue disease like Ehlers-Danlos, a spine anatomic abnormality, or an autoimmune disease are at high risk to develop degenerative disc disease. Once inflammation sets in, the disc softens, shrinks and slips out of its space, pressing against the spinal canal cover (dura and arachnoid layers).

The inflammation in the disc may spread to the arachnoid membrane and cauda equina nerve roots. As stated in Pathology #1, when inflammation produces sticky adhesions in the cauda equina nerve roots and arachnoid, they may glue together forming AA.

Early Symptoms

If the arachnoid becomes inflamed after trauma, epidural injection, spinal puncture or surgical procedure, there will be headaches, localized back pain, feverishness and dysphoria (a state of unease, depression and fatigue). This usually starts 7 to 10 days after the procedure or trauma.

When the cauda equina also becomes inflamed, the first early symptoms are shooting pains into the buttocks and legs, burning feet, and the tingling sensation of water or insects on the buttocks or legs.

Prevention of AA may be possible in these circumstances by use of one or more anti-inflammatory drugs that are effective inside the spinal canal. You can learn more about the symptoms and treatments for AA on our website.

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its research bulletins here.

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section.  

Arachnoiditis Is an Autoimmune Disease

By Dr. Forest Tennant

After several years and numerous studies, we have determined that Adhesive Arachnoiditis (AA) is an autoimmune disease – a condition in which autoantibodies or cellular elements erroneously recognize tissue as virulent or pathologic and attack it, producing inflammation and tissue destruction.

AA only occurs when inflammation forms jointly in the cauda equina and arachnoid membrane of the spine. After the inflammation becomes significant, adhesions form which fuse or “glue” cauda equina nerve roots to the arachnoid membrane. An autoimmune process is the generator and initiator of this inflammation.

The primary generator of the autoimmune process that causes AA is almost always reactivation of the Epstein-Barr virus (EBV) from its normal, dormant, parasitic state. EBV reactivation may occur multiple times over a lifetime.

This same process is now known to be a major causative factor in several cancers and other autoimmune diseases, including multiple sclerosis and systemic lupus erythematosus.

The autoimmune process of EBV has two components: autoantibodies and auto-reactivity. The latter occurs when the virus enters a cell and releases high amounts of self-antigen, which stimulates tissue destruction.

In rare cases, a virus other than EBV may generate autoimmunity and cause AA. Other viruses, especially cytomegalovirus, herpes 6, and covid, may also accelerate or potentiate EBV autoimmunity.

In the past it was generally assumed that epidural injections, spine surgery, contamination of spinal fluid by toxins, or spine trauma were the cause of AA. It is now known that these events may trigger EBV autoimmunity in spinal tissues. Our studies plainly show that AA is preceded and/or accompanied by other autoimmune conditions such as arthritis, migraine, and irritable bowel.

Medical practitioners and persons afflicted with AA must now recognize, diagnose, and treat AA as an autoimmune disease caused by EBV reactivation.

Doctors are more prone to want to treat a disease than they are to treat pain, so classifying AA as an autoimmune disease may improve pain treatment. I'm getting a lot of doctors who are coming on board with this, who see that a patient has a legitimate disease and don't mind prescribing some Vicodin, Tramadol, or Percocet to treat it.

More information about the Epstein-Barr Virus and its relationship to AA and other chronic pain conditions can be found in our book: "The Epstein-Barr Virus: A New Factor in the Care of Chronic Pain."  

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can also subscribe to its bulletins here.  

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section.    

Volunteers Needed for Arachnoiditis Study

By Pat Anson

Kathleen Haynes knows all about the physical and emotional pain that comes from adhesive arachnoiditis (AA), a progressive spinal disorder that causes severe intractable pain.  

She’s had AA for 50 years, after an oily contrast dye used for a myelogram imaging test was injected into her spinal column. The invasive test turned a simple back injury into a living nightmare, with the nerves in her lower spine becoming inflamed and sticking together.

“That oil stayed in my spinal column, surrounded my spinal nerves, and that’s why my nerves clumped together,” Haynes said. “And it just got worse and worse and worse, to the point where I use a wheelchair to get around.”

At the young age of 70, Haines is now pursuing a doctorate degree in Psychology at Walden University. For her dissertation, she’s doing a study about suicide ideation in AA patients. In the past, Haynes had suicidal thoughts herself.

“The pain was just unbearable. And not being believed that I was in pain and not getting the right medication,” she told PNN.

One of the things that was a deciding factor in doing this study was because I belong to a couple of AA groups on Facebook. And I was struck by the amount of people who go on there and say they're suicidal or say can you please lead me to somebody who does euthanasia?”  

KATHLEEN HAYNES

Haines’ goal is to interview 10 people with AA in the next few weeks who are not currently having suicidal thoughts, but are willing to talk about them. To protect their privacy, participants will be assigned numbers and their real names will not be used. A list of other conditions and sample questions can be found here, along with Haynes’ contact information.  

It’s not the just the pain that makes AA patients suicidal, according to Haynes. Other common factors are being disbelieved, ignored or marginalized by family, friends and doctors. Thoughts about “ending it all” occur so frequently that she thinks every AA patient should be evaluated for suicide ideation.   

“I want to see what people's common denominator is, in talking to them about their suicidality. The goal is to get this study together and get it out to the medical community because they barely recognize AA, yet alone the suicidality their patients face,” she said.

“They need to treat their patients with AA in a way that gives them a desire to live. And get them the treatment team, the providers that they need in order to live fairly comfortable life, despite their pain.” 

Like many other AA patients, Haynes had trouble being believed. She suffered her initial back injury while working for the U.S. Postal Service in the 1970’s, but only recently did the federal government approve her workers’ compensation claim, even though her AA diagnosis and disability happened a long time ago. The Massachusetts woman is now getting appropriate treatment and pain medication.        

To learn more about Haynes’ study and/or make a donation to her research, visit her GoFundMe page.